Scott E. Eggener to Survival Analysis
This is a "connection" page, showing publications Scott E. Eggener has written about Survival Analysis.
Connection Strength
0.445
-
Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.
Score: 0.092
-
Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4.
Score: 0.065
-
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
Score: 0.059
-
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.
Score: 0.054
-
Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974.
Score: 0.033
-
Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6.
Score: 0.028
-
Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.
Score: 0.024
-
Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63.
Score: 0.020
-
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
Score: 0.017
-
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8.
Score: 0.016
-
Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71.
Score: 0.014
-
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4905-11.
Score: 0.013
-
Long-term survival after "drop metastases" of renal cell carcinoma to the bladder. Urology. 2002 Oct; 60(4):697.
Score: 0.010